DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive drug targets brain tumors in early trial
Disease control Recruiting nowThis early-phase study tests a radioactive drug called 177Lu-PSMA-617 combined with standard chemotherapy (temozolomide) for people with aggressive IDH wild type gliomas. The goal is to see if the combination is safe and to get a first look at whether it helps control tumor growt…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for deadly brain tumors: Drug-Radiation combo trial opens
Disease control Recruiting nowThis study tests whether adding the drug VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG) in adults. About 10 participants aged 18 to 75 will receive the combination treatment. The main goal is t…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Phase: PHASE2 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for kids with relapsed cancers: experimental drug CBL0137 enters trial
Disease control Recruiting nowThis study tests a new drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink tumors. The…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC